Natural Killer Cell Tolerance to Self
自然杀伤细胞对自身的耐受性
基本信息
- 批准号:9433623
- 负责人:
- 金额:$ 52.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-01 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive Cell TransfersAllelesCRISPR/Cas technologyCellsComplexEventEvolutionFamilyGene ClusterGene FamilyGenesGenetic PolymorphismHumanImmuneImpairmentInflammatoryLaboratoriesLeadLectinLicensingMHC Class I GenesMaintenanceMajor Histocompatibility ComplexMalignant NeoplasmsMediatingMolecularMusMutant Strains MiceNK Cell ActivationNatural Killer CellsNormal CellNormal tissue morphologyPathologicProductionReceptor ActivationReceptor CellRegulationRoleSelf ToleranceSiteSpecificitySurveysTestingThinkingTissuesautoreactivitybeta-2 Microglobulincytokinegenome editingkiller immunoglobulin-like receptornovelreceptorreceptor functionresponsetumor
项目摘要
Abstract
Natural killer (NK) cell tolerance to self is incompletely understood despite wide-spread
acceptance of the now familiar “missing-self” hypothesis. Serving as a guiding principle for
several decades, it proposed that NK cells survey tissues for ubiquitously expressed major
histocompatibility complex class I (MHC-I) molecules as self. Normal levels of MHC-I do not
allow NK cell attack but if MHC-I is down-regulated in a pathologic event, NK cells attack. The
applicant and his laboratory discovered the Ly49 family of receptors specific for MHC-I
molecules and that inhibit NK cell activation receptor function, providing a molecular
explanation for the missing-self hypothesis. However, the missing-self hypothesis provides a
few predictions that were not observed, including the hypo-responsiveness of NK cells in
MHC-I-deficient hosts, rather than hyper-reactive NK cells. This can now be explained by more
recent findings from the applicant's laboratory that the Ly49 receptors have a second function to
license or educate NK cells to self-MHC-I, thereby generating appropriate self-tolerant NK cells.
Other unresolved issues regarding missing-self and NK cell tolerance remain unresolved, such
as if all tissues are protected by MHC-I from NK cell attack, the tissues expressing MHC-I that
confer licensing, and if Ly49s are solely responsible for licensing. Herein the applicant proposes
to study NK cell tolerance utilizing novel mice recently generated in his laboratory. In
particular, the Specific Aims of this proposal are to study: 1) Tissue-specificity and temporal
aspects of missing-self protection; 2) Tissue-specific induction and maintenance of licensed NK
cells; and 3) Role of Ly49s in licensing by self-MHC. These studies will enhance our
understanding of NK cell tolerance and the missing-self hypothesis.
抽象的
自然杀手(NK)对自我的耐受性不完全理解目的地广泛
接受现在熟悉的“失踪”假设。作为指导原则
几十年来,它提出NK细胞对无处不在的组织进行了调查
组织相容性复合物I类(MHC-I)分子作为自我。正常水平的MHC-I不
允许NK细胞攻击,但如果在病理事件中下调MHC-I,则NK细胞攻击。这
申请人及其实验室发现了特定于MHC-I的LY49接收器家族
分子并抑制NK细胞活化受体功能,提供分子
解释缺失的假设。但是,缺失的假设提供了
很少有未观察到的预测,包括NK细胞中的低反应性
MHC-I缺陷宿主,而不是过度反应的NK细胞。现在可以用更多
申请人实验室的最新发现,LY49受体具有第二个功能
许可或对NK细胞进行自我MHC-I的许可,从而产生适当的自我耐受性NK细胞。
关于失踪和NK细胞耐受性的其他未解决的问题仍未解决,这样
好像所有组织都受到NK细胞攻击的MHC-I保护,表达MHC-I的组织表明
会议许可,如果LY49是一个完全负责许可的。此处的申请人提案
使用最近在他的实验室中产生的新小鼠研究NK细胞耐受性。在
特别是,该提案的具体目的是研究:1)组织特异性和临时性
缺失自我保护的各个方面; 2)授权NK的组织特异性诱导和维护
细胞; 3)LY49在自我MHC许可中的作用。这些研究将增强我们的
了解NK细胞耐受性和缺失的假设。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wayne M. Yokoyama其他文献
Structural basis of MHCI antigen presentation sabotage by cowpox CPXV203
- DOI:
10.1016/j.molimm.2012.02.034 - 发表时间:
2012-05-01 - 期刊:
- 影响因子:
- 作者:
William H. McCoy;Xiaoli Wang;Wayne M. Yokoyama;Ted H. Hansen;Daved Fremont - 通讯作者:
Daved Fremont
Expression of a single inhibitory Ly49 receptor is sufficient to license NK cells for effector functions
单一抑制性 Ly49 受体的表达足以许可 NK 细胞发挥效应功能
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Sytse J. Piersma;Shasha Li;Pamela Wong;Michael D. Bern;Jennifer Poursine‐Laurent;Liping Yang;D. L. Beckman;Bijal A. Parikh;Wayne M. Yokoyama - 通讯作者:
Wayne M. Yokoyama
The mother-child union: the case of missing-self and protection of the fetus.
母子结合:自我缺失与胎儿保护案例
- DOI:
- 发表时间:
1997 - 期刊:
- 影响因子:11.1
- 作者:
Wayne M. Yokoyama - 通讯作者:
Wayne M. Yokoyama
Wayne M. Yokoyama的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wayne M. Yokoyama', 18)}}的其他基金
Infectious Disease/Immunology Stimulating Access to Research in Residency (ID/IMM StARR) Program at Washington University
华盛顿大学传染病/免疫学促进住院医师研究 (ID/IMM StARR) 项目
- 批准号:
10592699 - 财政年份:2023
- 资助金额:
$ 52.57万 - 项目类别:
ORIGINS AND FUNCTIONS OF UTERINE NATURAL KILLER CELLS IN PREGNANCY
妊娠期子宫自然杀伤细胞的起源和功能
- 批准号:
10451584 - 财政年份:2018
- 资助金额:
$ 52.57万 - 项目类别:
ORIGINS AND FUNCTIONS OF UTERINE NATURAL KILLER CELLS IN PREGNANCY
妊娠期子宫自然杀伤细胞的起源和功能
- 批准号:
10216997 - 财政年份:2018
- 资助金额:
$ 52.57万 - 项目类别:
ORIGINS AND FUNCTIONS OF UTERINE NATURAL KILLER CELLS IN PREGNANCY
妊娠期子宫自然杀伤细胞的起源和功能
- 批准号:
9980287 - 财政年份:2018
- 资助金额:
$ 52.57万 - 项目类别:
ORIGINS AND FUNCTIONS OF UTERINE NATURAL KILLER CELLS IN PREGNANCY
妊娠期子宫自然杀伤细胞的起源和功能
- 批准号:
9762839 - 财政年份:2018
- 资助金额:
$ 52.57万 - 项目类别:
Natural Killer Cell Control of Murine Cytomegalovirus Infection
自然杀伤细胞控制鼠巨细胞病毒感染
- 批准号:
10444730 - 财政年份:2017
- 资助金额:
$ 52.57万 - 项目类别:
相似海外基金
Next generation T cell therapies for mutant KRAS solid tumors
针对突变 KRAS 实体瘤的下一代 T 细胞疗法
- 批准号:
10731929 - 财政年份:2023
- 资助金额:
$ 52.57万 - 项目类别:
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer
HORMAD 特异性 TGF-β 耐药性记忆 T 细胞用于治疗胃食管癌患者
- 批准号:
10731407 - 财政年份:2023
- 资助金额:
$ 52.57万 - 项目类别:
Engineered TCR-T Cell Therapies Targeting Shared Tumor Associated Antigens
针对共享肿瘤相关抗原的工程 TCR-T 细胞疗法
- 批准号:
10324506 - 财政年份:2021
- 资助金额:
$ 52.57万 - 项目类别:
High-throughput Label-free Biosensor Platform for Rapid Detection of Antigen-specific T Cells with Single Cell Resolution
高通量无标记生物传感器平台,用于以单细胞分辨率快速检测抗原特异性 T 细胞
- 批准号:
10156407 - 财政年份:2021
- 资助金额:
$ 52.57万 - 项目类别:
Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations
致癌驱动突变特异性 CD4 T 细胞的治疗应用
- 批准号:
10640078 - 财政年份:2020
- 资助金额:
$ 52.57万 - 项目类别: